PMID- 8383283
OWN - NLM
STAT- MEDLINE
DCOM- 19930405
LR  - 20190904
IS  - 0098-1532 (Print)
IS  - 0098-1532 (Linking)
VI  - 21
IP  - 3
DP  - 1993
TI  - The use of nuclear morphometry to predict prognosis in pediatric urologic 
      malignancies: a review.
PG  - 222-9
AB  - Wilms tumor, the most common pediatric urologic malignancy, and genitourinary 
      rhabdomyosarcoma, the most common soft tissue sarcoma of childhood, represent two 
      of the most commonly diagnosed pediatric urologic malignancies. The introduction 
      and use of multimodal therapy (surgery, radiation, and chemotherapy) by the 
      National Wilms Tumor Study (NWTS) and the Intergroup Rhabdomyosarcoma Study (IRS) 
      groups have greatly improved the survival among children with these malignancies. 
      Present survival rates for Wilms tumor exceed 85% and for rhabdomyosarcoma 
      survival rates are approaching 80% as well. For Wilms tumor, current treatment 
      trends suggest less intense therapy for those children with favorable histology 
      tumors who are considered at relatively low risk for tumor recurrence. Likewise, 
      the significant morbidity associated with the present therapy regimens for 
      rhabdomyosarcomas has prompted investigators to search for individualized 
      management schemes for children with a high probability of responding. The need 
      for accurate criteria to separate these high and low risk groups becomes 
      imperative. In this review we present our work using nuclear morphometry, as a 
      prognostic indicator, to retrospectively predict response to therapy for children 
      with Wilms tumors and genitourinary rhabdomyosarcomas.
FAU - Partin, A W
AU  - Partin AW
AD  - Department of Urology, Johns Hopkins Hospital, Baltimore, MD 21205.
FAU - Gearhart, J P
AU  - Gearhart JP
FAU - Leonard, M P
AU  - Leonard MP
FAU - Leventhal, B G
AU  - Leventhal BG
FAU - Yoo, J K
AU  - Yoo JK
FAU - Crooks, D
AU  - Crooks D
FAU - Epstein, J I
AU  - Epstein JI
FAU - Beckwith, J B
AU  - Beckwith JB
LA  - eng
GR  - CA-15416/CA/NCI NIH HHS/United States
GR  - CA-42326/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Med Pediatr Oncol
JT  - Medical and pediatric oncology
JID - 7506654
SB  - IM
MH  - Adolescent
MH  - Cell Nucleus/*ultrastructure
MH  - Child
MH  - Child, Preschool
MH  - Combined Modality Therapy
MH  - Follow-Up Studies
MH  - Forecasting
MH  - Humans
MH  - Infant
MH  - Kidney Neoplasms/surgery/*ultrastructure
MH  - Prognosis
MH  - Remission Induction
MH  - Rhabdomyosarcoma/surgery/*ultrastructure
MH  - Signal Processing, Computer-Assisted
MH  - Survival Rate
MH  - Treatment Outcome
MH  - Urogenital Neoplasms/surgery/*ultrastructure
MH  - Wilms Tumor/surgery/*ultrastructure
EDAT- 1993/01/01 00:00
MHDA- 1993/01/01 00:01
CRDT- 1993/01/01 00:00
PHST- 1993/01/01 00:00 [pubmed]
PHST- 1993/01/01 00:01 [medline]
PHST- 1993/01/01 00:00 [entrez]
AID - 10.1002/mpo.2950210312 [doi]
PST - ppublish
SO  - Med Pediatr Oncol. 1993;21(3):222-9. doi: 10.1002/mpo.2950210312.